?? New Modulus Therapeutics Preprint ?? We've been really interested in reprogramming cell function in response to diverse environmental signals. In this new preprint, we describe our workflow for finding novel switch receptor designs, and how a comprehensive exploration of signaling space yields functions that would be nearly impossible to intuit or design by hand. https://lnkd.in/gCigviZJ Some highlights: - Switch receptors classically convert 'negative' extracellular signals to 'positive' signals. Here, however, we show that this behavior is much more analog than digital. Tuning specific signaling domain combinations yields a spectrum of function across multiple axes such as cytotox and persistence. - To our knowledge, this is the largest pooled screen ever done in NK cells, at 11,131 members, all in primary cells, using functional assays converted to be screening-compatible. - We observe hits from a diverse set of receptor domains, including cytokine receptor domains, and even receptors classically thought of as inhibitory, suggesting that 'tuning' of cell function via signaling is a lot more nuanced than expected if one merely puts receptors into coarse-grained buckets. Hats off to an amazing team that went from zero-to-one on this whole concept incredibly quickly! #celltherapy #nk #syntheticbiology #oncology #autoimmunedisease
关于我们
Modulus is engineering next-generation immune cell therapies, starting with Natural Killer cells rationally designed for the treatment of solid tumors. Modulus’ Convergent Design? platform combines genetic engineering, machine learning, and high-throughput in vivo screening to systematically converge on optimized cell designs. Modulus is committed to the discovery of cell therapies to treat a broad set of patient populations not currently served by existing treatments and will use its platform to enable partners and develop an internal pipeline of therapeutics.
- 网站
-
https://www.modulustherapeutics.com
Modulus Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Seattle,WA
- 类型
- 私人持股
- 创立
- 2020
地点
-
主要
US,WA,Seattle,98103
Modulus Therapeutics员工
动态
-
I'm excited to announce that Modulus Therapeutics has completed a transaction?with Ginkgo Bioworks, Inc. that will further strengthen?Gingko's?presence in the cell therapy engineering arena. We're really proud of the novel functionality we've been able to build into cell therapy candidates using custom immune receptors. With hundreds of new receptor designs now in the Ginkgo arsenal, we can't wait to see how Ginkgo's scale can help accelerate the adoption of these technologies! Massive thanks to the whole Modulus team that made this happen, and a special shoutout to the Ginkgo deal team, including Anna Marie Wagner and Brian Renda. Press release: https://lnkd.in/gn9KjbrP
Acquiring Modulus Therapeutics’ Cell Therapy Assets to Strengthen Next-Gen CAR Designs - Ginkgo Bioworks
https://www.ginkgobioworks.com